Huonslab Secures Formulation Patent for Recombinant Human Hyaluronidase Product, HYDIZYME™
Huonslab Co., Ltd., a subsidiary of Huons Global (KOSDAQ:084110), announced that it has obtained a patent for the formulation without serum albumin of HYDIZYME™ (Recombinant Human Hyaluronidase PH20, HLB3-002) in South Korea, bringing it closer to its goal of obtaining marketing authorization by 2026.
Huonslab Achieves Last-Patient-In (LPI) in Phase 1 Pivotal Study for Recombinant Human Natural Hyaluronidase PH20
Huonslab Co., Ltd. (“Huonslab”), a subsidiary of Huons Global (KOSDAQ:084110) has announced the successful completion of patient enrollment in its pivotal phase 1 clinical trial of Hydizyme™ (recombinant human natural hyaluronidase PH20; rHuPH20; HLB3-002), marking a significant milestone in the ongoing HLB3-002 development program. HLB3-002 Phase 1 Study (NCT06713317) was designed to evaluate the safety and allergenicity of HLB3-002 in 243 healthy volunteers.
Huonslab Announces Significantly Enhanced Bioavailability of SC Infliximab Co-formulated with HyDIFFUZE™ in Sprague-Dawley Rats; Abstract Selected for Presentation at AACR 2025
Huonslab Co., Ltd. ("Huonslab"), a subsidiary of Huons Global (KOSDAQ: 084110), today announced that its abstract titled “The Role of HyDIFFUZE™ in Co-formulation with Subcutaneous Infliximab” has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place on April 28, 2025.
Huonslab Announces Issuance of Process Patent for HyDIFFUZETM Drug Delivery Platform and MFDS IND Clearance for HLB3-002
Huonslab, Co. Ltd. (“Huonslab”), a subsidiary of Huons Global (KOSDAQ: 084110) today announced the registration of process patent covering the HyDIFFUZE™, rHuPH20 manufacturing methods by KIPO (Korean Intellectual Property Office).
